Transcript of Cardiotoxicity of Anticancer Drugs
Cardio-Oncology and Cardio- Oncological Prevention
Osuna Iturrios Daniela
Combination therapy often ampli!es cardiotoxicity, and radiotherapy
can also cause heart problems, particularly "hen combined "ith
chemotherapy
• $oday % s oncologists must be fully a"are of cardiovascular
risks to avoid or prevent adverse cardiovascular eects, and
cardiologists must no" be ready to assist oncologists by performing
evaluations relevant to the choice of therapy
There is a need for cooperation beteen these to areas and for the
develop!ent of a novel discipline" hich could be ter!ed
CA#D$O-ONCO%O&' O# ONCO- CA#D$O%O&'.
• $he discovery of ne" biomarkers to identify patients at a
high risk for the
development of these complications is a high priority
• &uidelines for cancer treatment that take cardiologic
conditions into
account are currently lacking and need to be developed
• Identi!cation of ne" compounds such as antioxidants and
endothelial- or cardiomyocyte-protective agents that can prevent
cardiotoxicity
• 'ssessment of cardiotoxicity should become part of phase I trials
to
develop agents "ith less risk
CONC%()$ON
• $here is a need to train a generation of (cardio-
oncologist) or (onco-cardiologist) investigators and clinicians to
overcome these communication gaps